In pancreatic cancer, Xu et al. discovered that downregulation of ALDOB, by reprogramming glucose metabolism, enhances the malignant behavior of tumor cells and leads to resistance to postoperative adjuvant transarterial chemoembolization (PA-TACE) 204. This evidence concerns the gene ALDOB and neoplasm.